Pseudodiastrophic Dysplasia

PURCHASE, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia. They describe their experiences and journey as caregivers through the difficult process of getting an accurate diagnosis and finding resources and support for their loved ones. In addition, they provide valuable insights on the key symptoms that define Lewy Body dementia, preparing for doctor visits and where to turn for resources and support. Episode 3: “What if it’s not Alzheimer’s: The Caregiver’s Perspective on Dementia with Lewy Bodies” is moderated by Lisa Ricciardi, Cognition’s chief executive officer, and features a conversation between: Norma LoebFounder and Executive Director Lewy Body Dementia Resource CenterMary Lou Falcone Founder, M.L. FALCONE, Public Relations Board member, LBD Resource Center Author: “I Didn't See It Coming, a Memoir of Love, Loss, and Lewy Body Dementia” This twenty-minute conversation is presented in three sections: Key symptoms and signs of Lewy body dementiaPreparing for a doctor visitCaring for the caregiver Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at conversations@cogrx.com. We’d love to hear your thoughts! About Lewy body dementiasLewy body dementias include Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB). PDD and DLB also share a constellation of symptoms including cognitive impairment, Parkinsonian mobility issues, visual hallucinations, and fluctuations of attention, with the timing of the onset of dementia relative to Parkinsonism being the major clinical distinction between DLB and PDD. An estimated 1.4 million Americans are living with Lewy body dementias, accounting for approximately 5-10% of all dementia cases. Lewy body dementias are characterized by a build-up of α-synuclein, which forms deposits called Lewy bodies and Lewy dendrites in the brain. Oligomers of α-synuclein are highly toxic and bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and loss. There are currently no disease-modifying treatments approved for these patients. About the SHIMMER trialCognition is conducting the double-blind Phase 2 SHIMMER study (COG1201) in adults with dementia with Lewy bodies (DLB). The clinical trial is designed to enroll 120 individuals between 50 and 80 years of age, who will be randomized to receive a placebo or one of two daily oral doses of CT1812 for six months. In addition to safety, this study will compare changes in cognitive performance, physical activity, and pharmacokinetic and pharmacodynamic biomarkers to baseline measurements. To learn more about the SHIMMER study and site locations please visit www.shimmerDLBstudy.com. The SHIMMER study is supported by $30M in grants by the National Institutes of Health’s National Institute on Aging (NIA). About Cognition TherapeuticsCognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com Health Care Disclaimer Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release and discussed on the podcast, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and expectations regarding Lewy body dementia treatment, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, our ability to secure new (and retain existing) grant funding, our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities Exchange Commission. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information:Cognition Therapeutics, Inc.  info@cogrx.com   Aline Sherwood (media)  Scienta Communications  asherwood@scientapr.com   Daniel Kontoh-Boateng / Rosalyn Christian (investors)  Tiberend Strategic Advisors, Inc.  dboateng@tiberend.com / rchristian@tiberend.com

PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia. In January 2022, Enterin announced statistically significant results from a randomized, placebo-controlled Phase 2b trial [KARMET] in 150 subjects with PD. In this study, a subset of those enrolled had PD-associated dementia. Patients treated with ENT-01 exhibited improvement in cognitive function compared with those receiving placebo. Statistically significant benefit was observed 6 weeks post treatment suggesting ENT-01 has potential to modify disease progression. “Our studies have demonstrated ENT-01’s clinical benefit across a range of PD related non-motor symptoms such as gastrointestinal dysfunction, dementia, psychosis, sleep architecture and circadian rhythm, all commonly associated with PD,” stated Denise Barbut, Enterin’s Co-Founder, President and CMO. The pathologic process in PD dementia (PDD) includes the presence of alpha-synuclein (αS) aggregates in the enteric nervous system (ENS) and central nervous system (CNS). Inhibiting αS aggregation in the ENS may reduce the continuing disease process in both the ENS and CNS and slow the progression of PD. ENT-01 is administered orally and acts locally on the ENS. It dislodges αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons. This effectively improves neural signaling between the gut and brain via the vagus nerve. “Through the Parkinson’s Virtual Biotech, we’re very excited to be working with Enterin as they look to develop a potential new treatment for Parkinson’s related dementia,” said Arthur Roach, Director of Research at Parkinson’s UK. “Parkinson’s is the fastest growing neurological condition in the world and currently there is no cure. The medications we have today can only treat and manage some of the more than 40 symptoms. “Whilst Parkinson’s is more commonly associated with motor symptoms like tremor, our community has asked us to make new and better treatments for Parkinson’s dementia a priority. We are encouraged by the clinical results that Enterin’s work has produced to date and look forward to the upcoming clinical trial which will have sites in the UK as well as in America.” “Enterin is very grateful to partner with such a prestigious and well-respected organization,” said David McCullough, CEO of Enterin. “We have worked closely with Parkinson’s UK and their clinical advisors to design a clinical study to evaluate ENT-01 in PD dementia. It is our hope that we can offer a new therapeutic option for these patients.” ENDS About Enterin Inc. Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community’s understanding of the link between infections, dysfunction of the ENS and the onset and progression of neurodegenerative disease. Enterin’s lead compound, ENT-01, displaces membrane-bound αS aggregates from nerve cells in the ENS and improves neural signalling between the gut and the brain The second compound, ENT-03, increases insulin sensitivity by acting at the level of the brain and acutely normalizes blood sugar in diabetic mice. ENT-03 is being developed for the treatment of diabetes, obesity and Alzheimer’s Disease. Studies in humans will begin in Q1 2023. For more information, please visit www.enterininc.com. ​ About Parkinson’s and Parkinson’s UK Parkinson’s is the fastest growing neurological condition in the world. Around 145,000 people in the UK have Parkinson’s. We are Parkinson's UK. Here for everyone affected by the condition. Funding research into the most promising treatments, taking us closer to a cure every day. Fighting for fair treatment and better services. Read more facts and statistics. Further information, advice and support is available on our website, www.parkinsons.org.uk or our free, confidential helpline on 0808 800 0303. About the Parkinson’s Virtual BiotechA groundbreaking approach to deliver life-changing new treatments in years not decades. Like other biotechs, the Parkinson’s Virtual Biotech uses cutting edge biological and chemical research to come up with new treatments. But it’s driven by people with Parkinson’s, not profit. Collaborative and agile, it adapts successful methods from the business world to deliver new treatments faster. Founded by Parkinson’s UK in 2017, the Parkinson’s Virtual Biotech is now an international programme in partnership with the Parkinson’s Foundation. We believe we’ll get to a cure faster by collaborating, not competing. To find out more, visit https://www.parkinsonsvirtualbiotech.co.uk/ Parkinson’s UK and the Parkinson’s Virtual Biotech: Emma Smithesmith@parkinsons.org.uk / pr@parkinsons.org.uk Enterin Inc:Katherine Wolfk.wolf@enterininc.com Investors:Lee Roth / Julia WeilmanBurns McClellanlroth@burnsmc.com / jweilman@burnsmc.com Media: Selina Husain / Robert Flamm, Ph.D.Burns McClellanshusain@burnsmc.com / rflamm@burnsmc.com

The ongoing 2022 Alzheimer's Association International Conference (AAIC) in San Diego has delivered a string of positive news for the AD space. We take a look at updates from Vivoryon, Anavex and Argentinian scientists below. Vivoryon Posts Promising Preclinical Evidence Of A Potential AD Drug Vivoryon shared two sets of preclinical data showcasing its N3pE amyloid-targeting therapeutic strategy's potential in mono- and combination therapy for Alzheimer's disease. N3pE amyloid (pGlu3-Abeta) is a toxic type of Abeta that hastens plaque aggregation and seeding, thus making it an important therapeutic target. N3pE amyloid that has formed can be catalyzed by QPCT, an enzyme expressed mainly by the learning and memory centers of the brain. Toxic N3pE is not found in healthy individuals. The company's first preclinical report (Poster P1-457) showed that combining the QPCT/L inhibitor varoglutamstat and the N3pE amyloid-specific PBD-C06 can help lower N3pE amyloid in vivo. Vivoryon evaluated whether a similar additive effect can be achieved if varoglutamstat is combined with Abeta-plaque-specific antibody aducanumab in a double transgenic mouse model that over expresses a variant of the human amyloid precursor protein and human QPCT. The animals were then given either varoglutamstat, chimeric aducanumab (chAdu) or a combination of both for 16 weeks and analyzed for accumulation markers. The scientists found that single agent treatment with either varoglutamstat or chAdu reduced N3pE and total Abeta accumulation in the brain. The effect for chAdu also appeared to be greater on total Abeta, while varoglutamstat led to a stronger drop in N3pE amyloid levels. In its second report (Poster P1-04), they explored the effect of 07/2a-k compared to 3D6-L in mice with AD. 3D6-L is a murine analog of bapineuzumab, a classical anti-Abeta antibody, while 07/2a-k is a CDC-mutant version of the PBD-C06 precursor 07/2a. Results from the study on mice showed that 07/2a-k had no effect on the biochemical or pathological Abeta measures, but it modestly improved memory based on the Novel Object Recognition task. It did not have any impact when the Barnes maze metric was used. The good thing is that 07/2a-k did not result in any micro- or macro hemorrhages, whereas 3D6-L induced a high number. Vivoryon is working on more preclinical trials to further assess the potential of PBD-C06. Anavex Shares First Complete Gene Pathway Data on Parkinson's Disease Dementia Study Anavex Life Sciences announced the first entire clinical gene pathway data from the Anavex 2-73-PDD-001 Parkinson's Disease Dementia PDD study. The randomized, placebo-controlled trial involved 132 PDD patients whose gene expressions were observed after 14 weeks. Pathway analysis showed the biological relevance of the PDD gene network and confirmed the effect of Anavex 2-73 on neurodegenerative illnesses, particularly PD and AD. "To my knowledge, this represents the first extensive transcriptomics analysis (RNAseq) of a therapeutic agent in patients with Parkinson's disease dementia (PDD). It is very intriguing to confirm this robust correlation of the clinical improvements of motor impairment (MDS-UPDRS) and cognition (CDR system) with compensation of expression levels of dysregulated neurodegenerative genes, especially Alzheimer's disease and Parkinson's disease, through the therapeutic effect of ANAVEX 2-73," Dr. Jaime Kulisevsky, M.D., Ph.D., the study's principal investigator said. "PDD is a debilitating disorder with significant co-morbidities and there has not been a mechanistically novel medication approved for PDD in over 20 years. Hence, new therapies are urgently needed to alleviate this suffering and disability," Kulisevsky added. Trial participants had the option to enroll in a voluntary 48-week open-label extension trial after completing Anavex 2-73-PDD-001. This study is ongoing. Argentinian Scientist Says Loss Of Smell From COVID-19 May Predict Disease Severity A group of scientists from Argentina found that persistent loss of the sense of smell related to COVID-19 may be a better indicator of the disease's severity and long-term effect in initial cases. Working with the Alzheimer's Association Consortium on Chronic Neuropsychiatric Sequelae of SARS-CoV-2 Infection, the scientists observed 766 adults ages 55 to 95 years who were exposed to COVID-19 for a year. After a series of physical, cognitive and neuropsychiatric tests were conducted, the researchers found that two-thirds of the participants showed functional memory impairment. Other metrics used showed similar outcomes, with 11.7% demonstrating memory-only impairment, 8.3% exhibiting attention and executive function impairment and 11.6% displaying multi-domain impairment. Of them all, persistent loss of smell was a common factor, especially in cognitive impairment. "The more insight we have into what causes or at least predicts who will experience the significant long-term cognitive impact of COVID-19 infection, the better we can track it and begin to develop methods to prevent it," Gabriela Gonzalez-Aleman, LCP, Ph.D., a professor at Pontificia Universidad Catolica Argentina, Buenos Aires, commented. Other notable findings that the scientists shared were the increased likelihood that intensive care unit stays will increase dementia risk and that introducing a positive life change amidst the pandemic may protect against symptoms of cognitive decline. "This study is an example of how investigators from diverse countries in Latin America and the United States, many of whom had never worked together before and had limited resources, came together under difficult circumstances but with a shared goal to advance scientific understanding about Alzheimer's, and the important contributions that such multicultural partnerships can yield," María Marquine, Ph.D., associate professor in the Departments of Medicine and Psychiatry and director of disparities research in the Division of Geriatrics, Gerontology and Palliative Care at the University of California, San Diego, noted.